Results of experience with a low-oestrogen combined contraceptive in 1,085 women showed that a dosage of less than 50 ,ug is compatible with satisfactory cycle control and efficacy. The preparation used in the trial, which contained 0-5 mg dl-norgestrel and 0 03 mg ethinyloestradiol, proved acceptable to most of the women.
Introduction
The Committee on Safety of Medicines recommended in 1969 that the dose of oestrogen used in oral contraceptives should, when possible, not exceed 50 ,ug, and the epidemiological evidence accumulated since that date suggests that the recommendation was soundly based (Adelstein, 1972) . The problem of lowering the oestrogen content is concerned not only with contraceptive efficacy but also with cycle control. The importance of the oestrogen component in controlling intermenstrual bleeding has been recognized from the earliest days of oral contraception and some of the reductions made in accordance with the recommendation to adopt 50 sLg as the standard dosage of oestrogen resulted in a very substantial increase in spotting and breakthrough bleeding. Thus, it appeared that a lower dose of oestrogen might entail an unacceptable loss of cycle control.
However, it appeared possible that a combined preparation containing norgestrel, because of its particular ability to postpone menstruation (Greenblatt, 1966) , might achieve the objective of controlling spotting and breakthrough bleeding with a lesser amount of oestrogen than usual.
The present trial was designed to assess the effect on reliability, cycle control, and tolerance of a further 4000 reduction in the oestrogen dose of a combined oral contraceptive.
Materials and Methods
Standard 21-tablet oral contraceptive packs were used, each tablet containing 0 5 mg dl-norgestrel and 0 03 mg ethinyloestradiol. The trial was conducted on a multicentre basis with a wide distribution throughout England and Wales. All women who were not barred from oral contraception by any usual contraindication were eligible for inclusion. Many women were traisferred directly from other oral contraceptives. Proof of fertility was not mandatory and many of the youngest women had not yet given proof of their fertility, but 82-1 00 of all subjects had previously been pregnant.
The age distribution of the subjects is shown in Patients kept a conventional daily record of their bleeding, which they were asked to describe as "spotting" only if it was so slight as to require no sanitary protection. Cycle length was corrected for misuse of the tablets-that is, when more or less than 21 tablets had been taken cycle length was calculated from the interval between the last tablet and the onset of bleeding as if 21 tablets had been taken. Symptoms were elicited by general inquiry rather than by systematic questioning about possible side effects. Other parameters studied included changes in blood pressure and weight and reasons for withdrawing from the trial.
PERIOD OF STUDY
The principal trial comprised 5,062 cycles in 623 women. A second group of 462 women kept the usual daily records of their bleeding, which were added to those of the principal group in the analysis of the bleeding pattern. The 2,261 cycles of the second group were used also in the calculation of the pregnancy rates. Other parameters analysed, however, are derived from the principal group alone.
Altogether, 1,085 women had taken the preparation for a total of 7,323 cycles at the time of the assessment. The longest duration of study was 22 cycles. The number of women who had completed each cycle up to that time is shown in fig. 1 Amenorrhoea.-This was defined as absence of withdrawal bleeding from any interval between courses of tablets, and occurred in 2-24",, of all cycles. This was rarely recurrent, and varied little throughout the study.
Duration of Withdrawal Bleeding.-The mean duration of withdrawal bleeding ("menstruation") for all cycles was 4-33 days.
Amount of Withdrawal Bleeding.-There was an overall decrease in the amount of menstrual loss, but to a lesser degree than with higher-dosed preparations ( fig. 3) .
Spotting.-This occurred in 880°, of all cycles. The first cycle figure of spotting in 14 500 of women was followed by a steady fall during the first seven cycles until the incidence of spotting became stabilized at rather less than 6",, of women per cycle. Altogether, 35 0, of women experienced spotting at some time during the trial, but of these 5800 did so in only one cycle and 790o in not more than two. The mean duration of spotting was 3-4 days and, like the percentage of affected cycles, it fell from the initial figure of 3-8 days to about 2 days in later cycles. Breakthrough Bleeding.-This occurred in 5 2°0 of all cycles. The incidence fell rapidly from an initial figure of 9-30 to a low point of 1 7" after 11 cycles. Altogether, 2100 of women had breakthrough bleeding at some time, but it was confined to a single cycle in 6300 of these and to not more than two cycles in 8200. The mean duration of breakthrough bleeding was 4 55 days, and it fell from an initial figure of 6-1 days to a low point of 1-3 days in cycle 12.
Total Intermenstrual Bleeding.-The mean duration of spotting for all cycles, including those in which spotting did not occur, was 0 3 days and the similar mean duration for breakthrough bleeding was 0-24 days. Thus, for all cycles, the mean intermenstrual bleeding is the sum of these two figuresthat is, 0 54 days per cycle.
Total Bleeding. Nevertheless, the part of such bleeding that precedes the tabletfree interval is classified as breakthrough bleeding, and the length of the next cycle is calculated from the start of withdrawal bleeding.
BREAKTHROUGH BLEEDING
The definition of breakthrough bleeding includes all bleeding occurring during the courses of tablets, except continuation of menstruation into the first three days of the next course, since it is not to be expected that withdrawal bleeding will stop immediately when the next course of tablets is begun.
WITHDRAWAL BLEEDING
The effect of these definitions is that the maximum duration of withdrawal bleeding is 10 days. A distinction is not made between bleeding and spotting in the tablet-free intervals since it is of no practical significance at that time, but it is reflected in the patients' statements about the amount of menstrual loss.
Since women cannot compare their bleeding with unknown normal standards (Hallberg et al., 1966) , the figures for the amount of loss have no absolute significance but can be accepted as indicating changes during the trial.
SIDE EFFECTS
The estimation of the side effects of oral contraceptives is particularly unsatisfactory. Where subjective effects are concerned it is now acknowledged that a placebo control period should be included in clinical trials if the influence of suggestion is to be minimized. In one clinical trial of 61 volunteers five (820°) were so severely affected by side effects that treatment had to be withdrawn during the placebo period. Weakness, fatigue, unsteady gait, mental confusion, headache, nervousness, insomnia, drowsiness, anorexia, nausea and vomiting, abdominal pains and cramps, and even rashes and multiple abnormalities of liver-function tests appeared among the placebo reactions in a survey of 67 placebo-controlled trials. Such reactions were not uncommon-vomiting, for instance, being as high as 8-5°o when the placebo was being compared with an oestrogen (Meyler and Herxheimer, 1966) . Placebo control is not generally possible in trials of oral contraceptives. Only one placebo-controlled trial of combined oral contraceptives has, in fact, been reported (Goldzieher et al., 1971) when the authors found a significantly higher first cycle incidence only of nausea and vomiting, headache, and nervousness, and only in respect of the high-oestrogen sequential pills. Goldzieher even found that 30°, of the placebo group had gained 5 lb (2-3 kg) or more in weight after four cycles. In the trial reported here, all symptoms during treatment lay within or close to the range found in the placebo period of Goldzieher's trial, and caution in ascribing them to the pill is therefore fully justified. The same caveat should apply to the reasons given for withdrawal from the trial, and the inclusion of a psychological reason in 420' of the ostensibly side-effectrelated withdrawals lends support to this view.
Conclusion
Our investigation supports the hypothesis that an effective combined oral contraceptive using norgestrel as the progestogen can employ as little as 30 ,ug of oestrogen.
The pregnancy rate of 0-16 per hundred woman-years, the mean intermenstrual bleeding of 0 54 days per cycle, and the mean total bleeding of 4-87 days per cycle indicate that the objectives of good control of fertility and the menstrual cycle have been met. The small percentage of "medical" withdrawals (14%) suggests a satisfactory level of acceptability. The low-oestrogen combined oral contraceptive can therefore be recommended for general use.
Introduction
The diagnosis and management of peripheral arterial disease depends on clinical and arteriographic findings. There is increasing awareness of the fact that arterial occlusions as seen on an aortogram may not always correspond with the severity of the patient's symptoms. Stenotic lesions, which seem unimportant on the x-ray picture, may in fact be responsible for a significant pressure drop and diminished blood flow. The introduction of the ultrasonic blood-flow velocity detector has made it possible to detect arteries which, while patent, are impalpable, because of proximal arterial occlusion, ankle swelling, or obesity.
In the present study this instrument has been used to record cuff occlusion pressures in the lower limbs of normal subjects and of patients with peripheral vascular disease. overlap. An aneroid manometer recording pressure in mm Hg is attached.
The brachial occlusion pressure is first recorded with the Doppler probe placed over the artery at the elbow. The pressure is read in both arms and the highest reading noted. In practice the difference in pressure between the two arms is seldom more than 5-10 mm Hg. If both legs are being studied it is advisable to record the brachial pressures again before the second limb is investigated. The most audible pedal pulse is then selected and the pencil-probe placed at this site at an angle of 45°. The thigh cuff is inflated above systolic pressure and then gradually let down, 5 mm at a time, until an arterial signal is again heard. This is taken to denote the thigh occlusion pressure. The same procedure is repeated with the calf and ankle cuffs, keeping the ultrasound probe directed to the same spot overlying a pedal artery.
When the test is performed after operation, care should be taken not to place the cuff over a tender area. This problem is most commonly met in the thigh after a femoropopliteal reconstruction. In these circumstances it is necessary to postpone the thigh readings until the tenderness subsides.
In this study we have expressed the cuff occlusion pressures at the thigh, calf, and ankle as a percentage of the brachial pressure. This makes it possible to compare not only pressure in different patients but also in the same subject when the pressures are taken on different occasions.
Patients Studied Sixty patients with intermittent claudication aged from 37 to 69 years of age were studied (see table) . Two patients underwent femoral arteriography, the remainder all had a translumbar aortogram. Ninety legs were found to have arterial occlusions, of which 45 were confined to the superficial femoral artery. The remaining 45 legs had an aortoiliac block, 25 of which had an associated block in the femoral artery.
Twenty-six patients undergoing vascular surgery were studied before and after operation. 
